semaglutide and cardiovascular outcomes in diabetes Timeline of outcome trials investigating cardiometabolic Series: Cardiovascular outcome trials for

The pill is licensed for adults with obesity (a BMI of 30 or above), or who are overweight (a BMI of 27 to 30) with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity

A physician must determine whether the patient fits the appropriate medical criteria and how GLP-1 therapy should fit into the larger care plan

Publishers note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers

Pathologically, SLE frequently exhibits a hypoxic state in local tissues due to abnormal activation of T and B cells, sustained immune-inflammatory reactions, and vascular damage

Consistently, DM significantly increased the cardiovascular mortality, all-cause mortality, hospitalization rate and prognosis of patients with HFpEF [30, 36, 37]